Research Topics
Species | J N RichSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The cancer stem cell: a new therapeutic paradigm?Jeremy N Rich
Expert Rev Anticancer Ther 6:1531-3. 2006- Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell linesJ N Rich
Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Biol Chem 274:35053-8. 1999..This suggests that the loss of p15(INK4B) may explain, in part, the selective loss of growth inhibition by TGF-beta in gliomas to form a more aggressive tumor phenotype... - Chemotherapy and cancer stem cellsJeremy N Rich
Department of Medicine, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
Cell Stem Cell 1:353-5. 2007..In this issue of Cell Stem Cell, Todaro et al. (2007) demonstrate that targeting tumor IL-4 sensitizes colon cancer stem cells to chemotherapy... - Gene expression profiling and genetic markers in glioblastoma survivalJeremy N Rich
Department of Medicine, W M Keck Center for Neuro Oncogenomics, Institute of Statistics and Decision Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 65:4051-8. 2005.... - Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer modelJeremy N Rich
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Biol Chem 278:15951-7. 2003..Genetically defined human cancer models offer useful tools in functional genomics to define the roles of specific genes in late stages of carcinogenesis... - The role of transforming growth factor-beta in primary brain tumorsJeremy N Rich
Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA
Front Biosci 8:e245-60. 2003..Early preclinical and clinical studies have shown promise of anti-TGF-beta strategies in the treatment of malignant gliomas suggesting TGF-beta may be a potential new therapeutic target in neuro-oncology... - ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumorsJeremy N Rich
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 11:8145-57. 2005..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies... - Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich
Duke University Medical Center, Box 2900, Durham, NC 27710, USA
J Clin Oncol 22:133-42. 2004..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma... - Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapySith Sathornsumetee
The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Drugs Today (Barc) 42:657-70. 2006..Phase II studies in other cancers have likewise been initiated. This review summarizes preclinical and clinical studies of vandetanib for the treatment of cancers... - A genetically tractable model of human glioma formationJ N Rich
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 61:3556-60. 2001..This model system will, for the first time, allow the biological significance of selected genetic alterations to be studied in human gliomas... - Cancer stem cells in radiation resistanceJeremy N Rich
Department of Medicine, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 67:8980-4. 2007..Hypoxia and stem cell maintenance pathways may provide therapeutic targets to sensitize cancer stem cells to cytotoxic therapies to improve cancer patient treatments... - Development of novel targeted therapies in the treatment of malignant gliomaJeremy N Rich
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Nat Rev Drug Discov 3:430-46. 2004 - Antiangiogenic therapy in malignant glioma: promise and challengeSith Sathornsumetee
The Preston Robert Tisch Brain Tumor Center, Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA
Curr Pharm Des 13:3545-58. 2007..In this review, we will discuss the current development, promise and challenge of antiangiogenic therapy in malignant glioma... - Brain cancer stem cells display preferential sensitivity to Akt inhibitionChristine E Eyler
School of Medicine, Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham North Carolina, USA
Stem Cells 26:3027-36. 2008..Together, these results suggest that Akt inhibitors may function as effective anticancer stem cell therapies... - c-Myc is required for maintenance of glioma cancer stem cellsJialiang Wang
Department of Surgery, Duke University, Durham, North Carolina, USA
PLoS ONE 3:e3769. 2008..As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells... - Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseShideng Bao
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Nature 444:756-60. 2006..Targeting DNA damage checkpoint response in cancer stem cells may overcome this radioresistance and provide a therapeutic model for malignant brain cancers... - Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cellsZhizhong Li
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
Cancer Cell 15:501-13. 2009..Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies... - NDRG4 is required for cell cycle progression and survival in glioblastoma cellsStephen H Schilling
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Biol Chem 284:25160-9. 2009..Collectively, these data indicate that NDRG4 is required for cell cycle progression and survival, thereby diverging in function from its tumor suppressive family member NDRG2 in astrocytes and GBM cells... - Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanSith Sathornsumetee
Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
J Clin Oncol 26:271-8. 2008.... - Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growthHui Wang
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, USA
Stem Cells 27:2393-404. 2009..Together, our data indicate that IL6 signaling contributes to glioma malignancy through the promotion of GSC growth and survival, and that targeting IL6 may offer benefit for glioma patients... - Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiformeChris A Learn
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 10:3216-24. 2004..However, this decrease does not effectively inhibit the biologically relevant processes of DNA synthesis, cellular growth, and invasion in cells expressing EGFRvIII... - Targeting cancer stem cells through L1CAM suppresses glioma growthShideng Bao
Department of Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 68:6043-8. 2008.... - A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growthQing Shi
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Mol Carcinog 46:488-96. 2007..TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy... - Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesisChristine E Eyler
Department of Pharmacology and Cancer Biology, Duke University Medical Center, PO Box 2900, Durham, NC 27710, USA
J Clin Oncol 26:2839-45. 2008..Identifying and targeting the molecular mechanisms responsible for CSC therapeutic resistance may improve the efficacy of current cancer therapies... - Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman
Departments of Surgery, Medicine, Pathology, Radiology, and Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 18:3522-8. 2000..We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity and maximum-tolerated dose (MTD) of BCNU in conjunction with the preadministration of O(6)-BG with recurrent or progressive malignant glioma... - Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinasesQ Shi
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Oncogene 26:4084-94. 2007..These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers... - Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiformeMichael A Badruddoja
Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
Neuro Oncol 9:70-4. 2007..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme... - New approaches to primary brain tumor treatmentSith Sathornsumetee
Departments of Medicine, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Anticancer Drugs 17:1003-16. 2006..It is probable, however, that targeted therapies will be most effective in combination either with one another or with cytotoxic therapies. In this study, we review the current state of new therapies for malignant gliomas... - The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasionAnita B Hjelmeland
Department of Surgery, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
Mol Cancer Ther 6:2449-57. 2007..These data suggest that the combination of LBT613 and RAD001 reduces glioma cell proliferation and invasion and support examination of the combination of RAF and TOR inhibitors for the treatment of human glioblastoma patients... - Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapyMary Lou Affronti
Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
Cancer 115:3501-11. 2009..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated... - Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaJennifer A Quinn
Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
J Clin Oncol 27:1262-7. 2009.... - Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activationQing Shi
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
J Biol Chem 279:52200-9. 2004..As tumor cells face stressful microenvironments particularly during the process of invasion, these results suggest that SPARC functions, in part, to promote tumor progression by enabling tumor cells to survive under stressful conditions... - Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factorShideng Bao
Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
Cancer Res 66:7843-8. 2006..Together these data indicate that stem cell-like tumor cells can be a crucial source of key angiogenic factors in cancers and that targeting proangiogenic factors from stem cell-like tumor populations may be critical for patient therapy... - SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motilityMark D Hjelmeland
Division of Neurology, Duke University Medical Center, P.O. Box 2900, Durham, NC 27710, USA
Mol Cancer Ther 3:737-45. 2004..Together, our results suggest that small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility... - Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activityAnita B Hjelmeland
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Cancer Res 65:11276-81. 2005..Thus, the loss of PTEN expression in human cancers may contribute to a role for TGF-beta as a tumor enhancer with specific effects on cellular motility and invasion... - Bevacizumab plus irinotecan in recurrent glioblastoma multiformeJames J Vredenburgh
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 25:4722-9. 2007..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan... - Diagnosis and treatment of high-grade astrocytomaSith Sathornsumetee
Division of Neurology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA
Neurol Clin 25:1111-39, x. 2007..It is probable that targeted therapies will be most effective in combination with one another or with cytotoxic therapies. This article discusses diagnosis and current treatment of high-grade astrocytomas... - Notch promotes radioresistance of glioma stem cellsJialiang Wang
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Stem Cells 28:17-28. 2010..Taken together, our results suggest a critical role of Notch signaling to regulate radioresistance of glioma stem cells. Inhibition of Notch signaling holds promise to improve the efficiency of current radiotherapy in glioma treatment... - The emerging role of anti-angiogenic therapy for malignant gliomaDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Curr Treat Options Oncol 9:1-22. 2008..Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy... - A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:182-9. 2008..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide... - Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Neuro Oncol 10:330-40. 2008..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population... - Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastomaSridharan Gururangan
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:745-51. 2008..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence... - Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaJennifer A Quinn
Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
Neuro Oncol 11:556-61. 2009..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG... - Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasAnnick Desjardins
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 14:7068-73. 2008..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma... - Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiformeJennifer A Quinn
Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 15:1064-8. 2009.... - Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibitionRanjit K Goudar
Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
Mol Cancer Ther 4:101-12. 2005..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy... - Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
J Clin Oncol 24:115-22. 2006..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients... - Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon
Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 23:9359-68. 2005.... - Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 104:1478-86. 2005..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)... - Chemotherapy and novel therapeutic approaches in malignant gliomaAnnick Desjardins
The Brain Tumor Center, Department of Pediatrics, Duke University Medical Center, 047 Baker House, Trent Drive, Box 3624, Durham, NC 27710, USA
Front Biosci 10:2645-68. 2005..In this article, we review the past, present and future treatments of malignant gliomas with a special interest on chemotherapy, resistance mechanisms and tyrosine kinase inhibitors... - Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 20:2277-83. 2002.... - Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 103:329-38. 2005..In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease... - Phase II trial of temozolomide in patients with progressive low-grade gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 21:646-51. 2003..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma... - Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 6:145-53. 2004.... - Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon
AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
Clin Cancer Res 12:860-8. 2006.... - Recent advances in the treatment of malignant astrocytomaDavid A Reardon
Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 24:1253-65. 2006..The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival... - Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 20:1389-97. 2002..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma... - Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh
The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 13:1253-9. 2007..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma... - Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins
Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
J Neurooncol 83:53-60. 2007..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)... - Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathwaysZhizhong Li
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Biol Chem 284:16705-9. 2009..In this minireview, we summarize recent data regarding critical signaling pathways involved in brain tumor stem cell biology and discuss how targeting these molecules may contribute to the development of novel anti-glioma therapies... - AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant gliomaSith Sathornsumetee
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Cancer Res 66:8722-30. 2006.... - New treatment strategies for malignant gliomasSith Sathornsumetee
The Preston Robert Tisch Brain Tumor Center Division of Neurosurgery Neuro Oncology, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA
Expert Rev Anticancer Ther 6:1087-104. 2006..Predictive biomarkers will enrich for patients most likely to respond in future clinical trials. Additional clinical studies will combine novel targeted therapies with radiation, chemotherapies and immunotherapies... - Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
J Nucl Med 47:912-8. 2006.... - Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 6:134-44. 2004..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic... - Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biologyMichael T Forrester
Department of Biochemistry, Medical Scientist Training Program, Duke University Medical Center, Durham, NC 27710, USA
Biotechniques 50:41-5. 2011..This technique boosts endogenous cellular consumption of NO, thus providing a simple and efficacious approach to studying mammalian NO biology that can be employed as both a primary experimental and confirmatory tool... - Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsD A Reardon
1 Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA 2 Department of Pediatrics, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
Br J Cancer 107:1481-7. 2012.... - Distinct requirements for Ras oncogenesis in human versus mouse cellsNesrin M Hamad
Department of Pharmacology, Division of Neurology, Duke University Medical Center, Durham North Carolina 27710, USA
Genes Dev 16:2045-57. 2002..Thus, oncogenic Ras may transform murine and human cells by distinct mechanisms, and the RalGEF pathway--previously deemed to play a secondary role in Ras transformation--could represent a new target for anti-cancer therapy... - Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomasS Gururangan
Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 3:246-50. 2001..Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days... - Molecularly targeted therapy for malignant gliomaSith Sathornsumetee
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 110:13-24. 2007..In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma... - Neurofibromatosis type 2S Sathornsumetee
Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Neurology 68:E14. 2007 - Hypoxia and hypoxia inducible factors in cancer stem cell maintenanceZhizhong Li
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Curr Top Microbiol Immunol 345:21-30. 2010..These findings illustrated a new mechanism through which oxygen tension and microenvironment influences cancer development. Targeting hypoxia niches may therefore improve therapy efficacy by eliminating cancer stem cell population... - Making a tumour's bed: glioblastoma stem cells and the vascular nicheRichard J Gilbertson
Department of Developmental Neurobiology and Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA
Nat Rev Cancer 7:733-6. 2007..These data have direct implications for cancer, highlighting the similarity between normal and malignant stem cells and identifying the tumour microenvironment as a target for new therapies... - EGFR mutations and sensitivity to gefitinibJeremy N Rich
N Engl J Med 351:1260-1; author reply 1260-1. 2004 - Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathwayShideng Bao
The Key Laboratory for Cell Biology and Tumor Cell Engineering, The Ministry of Education of China, The School of Life Sciences, Xiamen University, Fujian 361005, China
Cancer Cell 5:329-39. 2004..These data demonstrated that the survival-promoting function is crucial for periostin to promote tumor metastasis of colon cancer...
Research Grants
- TGF BETA AND BRAIN TUMORSJeremy Rich; Fiscal Year: 2002....
- Molecular Mechanisms of SPARC Mediated Glioma InvasionJeremy Rich; Fiscal Year: 2007..These studies will contribute to the understanding of the regulation of glioma invasion and provide the basis of novel targeted therapies for gliomas. ..
- The Roles of Osteonectin and Osteoactivin in GliomasJeremy Rich; Fiscal Year: 2007..2) Validate osteonectin and osteoactivin as potential therapeutic targets in glioma invasion. It is hoped that these studies will provide the basis of novel therapeutic interventions for patients with malignant gliomas. ..
- TGFbeta-PTEN Interactions in Glioma Biology & TherapyJeremy Rich; Fiscal Year: 2007..Any promising new therapies can be directly translated into clinical trials at the Preston Robert Tisch Brain Tumor Center. ..